Clinical Trial - Trial KCT0006973
Access comprehensive clinical trial information for KCT0006973 through Pure Global AI's free database. This Phase 2 trial is sponsored by Yonsei University Health System, Severance Hospital and is currently Not yet recruiting. The study focuses on Non-small cell lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Korean Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
KCT0006973
Phase 2
Not yet recruiting
Trial Details
Korean Clinical Trial Registry • KCT0006973
Untitled Trial
Window of opportunity trial of durvalumab (MEDI4736) to identify immune dynamics in operable non-small cell lung cancer (NSCLC) (MIRACLE)
Study Focus
Interventional
Sponsor & Location
Yonsei University Health System, Severance Hospital
AstraZeneca Korea
South Korea
Timeline & Enrollment
Phase 2
N/A
N/A
ICD-10 Classifications
Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Middle lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung
Data Source
Korean Clinical Trial Registry
KCT0006973
Non-Device Trial